Sagimet's fatty liver disease drug shows promise in trial (updated)

Sagimet Biosciences

22/01/2024 12:23

(Adds study details in paragraphs 2, 4; share movement in
paragraph 3)
       Jan 22 (Reuters) - Sagimet Biosciences  SGMT.O  said on
Monday its experimental drug was statistically significant in
reducing symptoms of a fatty liver disease in a mid-stage study.
    However, the company said that nearly 20% of patients
dropped out of the study due to adverse events that emerged
during treatment with the drug, versus 5.4% for the patients
treated with a placebo. 
    Sagimet's shares were up 2% at $6.9 in premarket trading. 
    The drug developer said it plans to hold a meeting with the
U.S. Food and Drug Administration and begin the late-stage study
of the drug in the second half of this year.

 (Reporting by Khushi Mandowara in Bengaluru; Editing by
Shinjini Ganguli and Shailesh Kuber)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))